Please call your physician’s office before coming in for your appointment if you have symptoms of a cough, fever, or difficulty breathing; traveled to Europe or China or other areas impacted by the coronavirus (COVID-19) within the past 14 days; been in close contact with someone who has traveled outside the U.S. to one of the impacted countries; or may have been exposed to the coronavirus. Effective Monday May 18th all VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. FOR THE LATEST UP TO DATE INFORMATION, ALERTS AND CANCELLATIONS PLEASE CLICK HERE

Alex Spira, MD, PhD, FACP

VCS Physicians

Alex Spira, MD, PhD, FACP Headshot

Getting a diagnosis of cancer is the most challenging thing any patient and family will have to go through. My job is to provide the most comprehensive options for patients, with state-of-the-art care and compassion.

Work and Credentials:

Primary Location

Fairfax Office

Position

Medical Oncologist

Board Certification

Medical Oncology and Internal Medicine

Fellowship

Johns Hopkins Hospital, Medical Oncology

Internship

Hospital of the University of Pennsylvania

Residency

Hospital of the University of Pennsylvania

Medical School

New York University School of Medicine

College

Harvard University

Dr. Alex Spira earned his medical degree from the New York University School of Medicine. He then went on to complete his internship and residency at the Hospital of the University of Pennsylvania, and his medical oncology fellowship at Johns Hopkins Hospital. During his training, Dr. Spira was granted many awards and honors, and he completed several specialized fellowship programs. Among these honors were the National Institutes of Health Medical Scientist Training Program Fellowship (1990-1997), Merck Corporation Scholarship (1995-1995), Pediatric AIDS Foundation Fellowship (1993- 1995) and Harvard University Scholarship (1987-1990). Dr. Spira has also received his PhD from the New York School of Arts and Sciences.

As Director of the Virginia Cancer Specialists (VCS) Research Institute and the Phase I Trial Program, Dr. Spira is actively involved in advancing medicine and offering targeted treatment options for patients. Although his research interests are numerous, Dr. Spira particularly enjoys studying immunotherapy, personalized medicine, GI, thoracic and lung cancer and sarcomas. Dr. Spira is also Co-Chair of the USOncology Thoracic Oncology Committee, Chair of the USOncology Research Executive Committee, and member of the USOncology National Policy Board Executive Committee. Dr. Spira is a faculty member at Johns Hopkins School of Medicine, and serves as Assistant Professor of Oncology.

Throughout his career, Dr. Spira has been recognized as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine for multiple years. In 2014, he received the prestigious “Castle Connolly America’s Top Doctor” award. In his spare time, Dr. Spira enjoys spending time with his family, coaching children’s sports, cycling, and cheering on his favorite New York sports teams.



 


 

Practice Blog

September 8, 2017

Alex Spira, MD, PhD, FACP

Read More

Physician Publications

June 16, 2020

Interview with Dr. Alex Spira - Medpage Today Lung Cancer and Covid19

Read More
June 7, 2020

Camidanlumab Tesirine, an Antibody-Drug Conjugate, in Relapsed/Refractory CD25-positive Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia: A Phase I Study

Read More
May 28, 2020

Virginia Cancer Specialists Investigators Neelima Denduluri, MD & Alex Spira, MD, PhD, FACP Present Data Highlighting Key Advances in Oncology Research - 2020 ASCO Annual Meeting & Expo

Read More

More Publications by Alex Spira, MD, PhD, FACP

April 9, 2020

Alex Spira, MD PhD FACP VCS Co-Author Virginia Cancer Specialists - JAMA Network - Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas Clinical Trial

Read More
April 7, 2020

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue SarcomasThe ANNOUNCE Randomized Clinical Trial

Read More
October 1, 2019

A review of canakinumab and its therapeutic potential for non-small cell lung cancer.

Read More
August 1, 2019

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.

Read More
August 1, 2019

Detection of NRG1 Gene Fusions in Solid Tumors.

Read More
April 2, 2019

Alexander Spira, MD, PhD, FACP, on the recent approval of atezolizumab in SCLC

Read More
February 4, 2019

Virginia Cancer Specialists (VCS) Now Offering a Newly FDA-Approved Targeted Therapy for Acute Leukemia

Read More
October 8, 2018

Advancements in Science and Cancer Care Research Announced at the US Oncology Research 17th Annual Science Forum - Dr. Alex Spira

Read More
September 25, 2018

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

Read More
September 25, 2018

Co Author Alex Spira, MD - Lung Cancer Study Treatment Option for ALK Positive Lung Cancer Patients

Read More
September 20, 2018

Alex Spira, M.D., PhD, F.A.C.P. receives award for his work in Lung Cancer

Read More
May 22, 2018

Virginia Cancer Specialists Collaborating with Caris Life Sciences to Present New Molecular Findings at the 2018 ASCO Annual Meeting

Read More
April 26, 2018

Dr. Alex Spira quoted in announcement from Mirati Theraputics: Progress Of Lead Programs And Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials

Read More
March 6, 2018

Virginia Cancer Specialists first patient successfully completes Cycle 1 of Treatment with PCM-075 combination with Low Dose Cytarabine (LDAC) AML Trial

Read More
February 15, 2018

Alex Spira, MD Co-Author of collaborative study on Immunotherapy guidelines to guide clinicians and patients

Read More
February 7, 2018

Virginia Cancer Specialists enrolls fist patient in Phase 1b/2 Clinical Trial of PCM-075 for Acute Myeloid Leukemia (AML)

Read More
January 30, 2018

Northern Virginia 2018 Thoracic Oncology Symposium, CME Program - March 10th 2018

Read More
March 9, 2016

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Read More
September 14, 2015

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

Read More
June 3, 2013

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

Read More
February 1, 2013

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Read More
January 2, 2013

Expert Insight: Adjuvant Therapy Fails for High-Risk Soft Tissue Sarcoma

Read More
June 1, 2012

Phase II study of two eribulin regimens in combination with erlotinib in patients (pts) with previously treated advanced non-small cell lung cancer

Read More
April 16, 2012

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

Read More
January 1, 2012

Clinical trial design in the age of molecular profiling.

Read More
September 8, 2011

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

Read More
June 1, 2011

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

Read More
June 1, 2011

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).

Read More
June 1, 2011

Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients

Read More
December 4, 2010

Serotonin Dysregulation Correlates with Both Bone and Active Disease In Multiple Myeloma.

Read More
December 1, 2010

Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer.

Read More
December 3, 2009

Use of an ex vivo multiplexed signal pathway inhibitor treatment to reveal sensitivity of myeloma and nonmyeloma bone marrow cell populations.

Read More
December 1, 2009

Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.

Read More
January 22, 2004

Multidisciplinary Management of Lung Cancer

Read More
January 1, 2002

The use of Chemotherapy in Soft Tissue Sarcomas

Read More

Clinical Trials (61)

Clinical Trial 19192

A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY,IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1-SELECTED NON-SMALL CELL LUNG CANCER (GO41717)


Clinical Trial 19143

20190009: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C


Clinical Trial APG-115-US-002


Clinical Trial KL26401

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors who are refractory to Available Standard Therapies


Clinical Trial 19043

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)


Clinical Trial 19082

A PHASE 1/1B MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS (CPI-006-001)

All Clinical Trials for Alex Spira, MD, PhD, FACP

Clinical Trial 19192

A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY,IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1-SELECTED NON-SMALL CELL LUNG CANCER (GO41717)

ClinicalTrials.gov ID:

NCT04294810

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19143

20190009: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C

ClinicalTrials.gov ID:

NCT04303780

ClinicalTrials.gov Link:

Click Here


Clinical Trial APG-115-US-002
Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03611868

ClinicalTrials.gov Link:

Click Here


Clinical Trial KL26401

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors who are refractory to Available Standard Therapies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04152499

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19043

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03964727

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19082

A PHASE 1/1B MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS (CPI-006-001)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03454451

ClinicalTrials.gov Link:

Click Here


Clinical Trial TPX-005-001

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

ClinicalTrials.gov ID:

NCT03093116

ClinicalTrials.gov Link:

Click Here


Clinical Trial PSB205

A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients with Relapsed/ Refractory Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03986606

ClinicalTrials.gov Link:

Click Here


Clinical Trial PLX124-01

A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Advanced Malignancies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03297424

ClinicalTrials.gov Link:

Click Here


Clinical Trial RMC-4630-02

A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors with Specific Genomic Aberrations

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03989115

ClinicalTrials.gov Link:

Click Here


Clinical Trial ASTX295-01

Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03975387

ClinicalTrials.gov Link:

Click Here


Clinical Trial 849-001

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03785249

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19081

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03319628

ClinicalTrials.gov Link:

Click Here


Clinical Trial KL166-I-01

A Phase I-II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (by IHC) Solid Tumors who did not Respond or Stopped Responding to Approved Therapies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03602079

ClinicalTrials.gov Link:

Click Here


Clinical Trial 14059

Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT3379428


Clinical Trial 101-18101

An Open-label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03928314

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18214

A PHASE 1/2 STUDY OF GALINPEPIMUT-S IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH SELECTED ADVANCED CANCERS (SLS17-201/MK3475-770)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03761914

ClinicalTrials.gov Link:

Click Here


Clinical Trial LOXO-RET-18037

A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03906331

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19024

Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (20170543)


Clinical Trial GO-005

A Phase 1/2 Study of GRT-C903/GRT-R904, a Vaccine Targeting Shared Neoantigens, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03953235

ClinicalTrials.gov Link:

Click Here


Clinical Trial M14-239

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03539536

ClinicalTrials.gov Link:

Click Here


Clinical Trial C2321001

A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03460977

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18129

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03596866

ClinicalTrials.gov Link:

Click Here


Clinical Trial 1951-CL-0101

A Phase 1 Study of ASP1951 in Subjects with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03799003

ClinicalTrials.gov Link:

Click Here


Clinical Trial LOXO-RET-17001

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03157128

ClinicalTrials.gov Link:

Click Here


Clinical Trial CP-MGC018-01

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti–PD-1 Antibody) in Patients with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03729596

ClinicalTrials.gov Link:

Click Here


Clinical Trial AO-176-101

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03834948

ClinicalTrials.gov Link:

Click Here


Clinical Trial ARYS-002

An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03696212

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18-234

(AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03846310

ClinicalTrials.gov Link:

Click Here


Clinical Trial GO-004

An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03639714

ClinicalTrials.gov Link:

Click Here


Clinical Trial KL 166-I-01

A Phase I-II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (by IHC) Solid Tumors who did not Respond or Stopped Responding to Approved Therapies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03602079

ClinicalTrials.gov Link:

Click Here


Clinical Trial AMXT1501-101A

PHASE I DOSE-FINDING, SAFETY STUDY OF ORAL AMXT 1501 DICAPRATE AND DIFLUOROMETHYLORNITHINE (DFMO) IN PATIENTS WITH ADVANCED SOLID TUMORS

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03536728

ClinicalTrials.gov Link:

Click Here


Clinical Trial Bayer 18594

An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03188965

ClinicalTrials.gov Link:

Click Here


Clinical Trial Janssen 61186372EDI10051

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT02609776

ClinicalTrials.gov Link:

Click Here


Clinical Trial 17143

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03318939

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18033

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)


Clinical Trial GO-003

An Observational Feasibility Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine in Patients with Advanced Cancer

Locations:

Fairfax Office


Clinical Trial ADCT-402-201

Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03589469

ClinicalTrials.gov Link:

Click Here


Clinical Trial 17-167

A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

ClinicalTrials.gov ID:

NCT03447769

ClinicalTrials.gov Link:

Click Here


Clinical Trial 1948-CL-0101

A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03565445

ClinicalTrials.gov Link:

Click Here


Clinical Trial TROV-052

A Phase 1b/2 Study of PCM-075 in Combination with either Low-Dose Cytarabine or Decitabine in Subjects with Acute Myeloid Leukemia (AML)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03303339

ClinicalTrials.gov Link:

Click Here


Clinical Trial CTMX-M-2029-001

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03543813

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18-057

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03369223

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18-020

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03400332

ClinicalTrials.gov Link:

Click Here


Clinical Trial Astex ASTX029

Study of ASTX029 in Subjects With Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03520075

ClinicalTrials.gov Link:

Click Here


Clinical Trial 17-140

A Phase III, Double-Blinded, Multi-center, Randomized Study Evaluating The Efficacy and Safety of Neo-adjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer


Clinical Trial STRO-001-BCM1

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03424603

ClinicalTrials.gov Link:

Click Here


Clinical Trial DS1062-A-J101

First-in-human Study of DS-1062a for Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03401385

ClinicalTrials.gov Link:

Click Here


Clinical Trial BGB-A317

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors.

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT02660034

ClinicalTrials.gov Link:

Click Here


Clinical Trial Tesaro 4020-01-001

A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT02817633

ClinicalTrials.gov Link:

Click Here


Clinical Trial R3767-ONC-1613

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03005782

ClinicalTrials.gov Link:

Click Here


Clinical Trial CTMX-M-2009-001

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors(PROCLAIM-CX-2009)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03149549

ClinicalTrials.gov Link:

Click Here


Clinical Trial 8374-CL-0101

A Phase 1 Study of ASP8374, an Immune Checkpoint Inhibitor, in Subjects with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03260322

ClinicalTrials.gov Link:

Click Here


Clinical Trial M16-074

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects with Locally Advanced or Metastatic Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03071757

ClinicalTrials.gov Link:

Click Here


Clinical Trial M14-237

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT02099058

ClinicalTrials.gov Link:

Click Here


Clinical Trial STARTRK-2

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of patients with locally advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements.

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT02568267

ClinicalTrials.gov Link:

Click Here


Clinical Trial Mirati 516-001

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies


Clinical Trial MRTX-500

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT02954991

ClinicalTrials.gov Link:

Click Here


Clinical Trial AbbVie M15-862

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927, an Immunotherapy, in Subjects with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT02988960

ClinicalTrials.gov Link:

Click Here


Clinical Trial AbbVie M15-891

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, a Monoclonal Antibody, in Subjects with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03000257

ClinicalTrials.gov Link:

Click Here


Clinical Trial 16-006

A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen (MS200095-0022)

ClinicalTrials.gov ID:

NCT02864992

ClinicalTrials.gov Link:

Click Here

Primary Location

Fairfax Office Office

Fairfax Office

Learn More

Other Locations

Awards

January 1, 2020

2020 Virginia Living Top Doctors


November 1, 2019

2019 Washingtonian magazine Top Doctors


January 1, 2019

Northern Virginia Magazine Top Doctor 2019


January 1, 2018

2018 Washingtonian Magazine Top Doctor Nomination


November 1, 2017
Washingtonian Magazne Top Doctors 2017

Washingtonian Magazne Top Doctors 2017


March 9, 2016
Washingtonian Magazine

Washingtonian Top Doctor 2016


September 1, 2015
Washingtonian Magazine

Washingtonian Top Doctor 2015


February 1, 2015
Northern Virginia Magazine

Top Doctor 2015


January 31, 2014
Northern Virginia Magazine

Top Doctor 2014